Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.